New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder

NEXT STORY
Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use
PREV STORY
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas

BERKELEY, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical ...

author_avatar
NASDAQ Market News

New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia

author_avatar
NASDAQ Market News

U.S. News & World Report Recognizes NYC Health + Hospitals/Coney Island as High Performing in Heart Failure

Brooklyn, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- NYC Health + Hospitals/Coney Island announced ...

author_avatar
NASDAQ Market News